RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.

@article{FloresPrez2014RAD50TI,
  title={RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.},
  author={Ali Flores-P{\'e}rez and Lourdes E Rafaelli and Nayeli Ram{\'i}rez-Torres and Elena Ar{\'e}chaga-Ocampo and Sara Fr{\'i}as and Silvia M S{\'a}nchez and Laurence A. Marchat and Alfredo Hidalgo-Miranda and Valeria Quintanar-Jurado and Sergio Arturo Rodr{\'i}guez-Cuevas and Ver{\'o}nica Bautista-Pi{\~n}a and {\'A}ngeles Carlos-Reyes and C{\'e}sar L{\'o}pez-Camarillo},
  journal={Cancer biology & therapy},
  year={2014},
  volume={15 6},
  pages={777-88}
}
In tumor cells the effectiveness of anti-neoplastic agents that cause cell death by induction of DNA damage is influenced by DNA repair activity. RAD50 protein plays key roles in DNA double strand breaks repair (DSBs), which is crucial to safeguard genome integrity and sustain tumor suppression. However, its role as a potential therapeutic target has not been addressed in breast cancer. Our aim in the present study was to analyze the expression of RAD50 protein in breast tumors, and evaluate… CONTINUE READING